Beam turns its soaring valuation into new assets, buying out an under-the-radar spinout and their gene delivery tech
Base editing has attracted major attention since David Liu first managed to swap one DNA letter for another in cell lines five years ago. Actually pulling that off in large animals or humans, though, has always faced several major hurdles, including: How do you actually get it to the right tissue? What delivery vehicle is both big enough to carry all that clunky protein machinery and targeted enough to guide it to the right place?
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.